Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in December 1981 and is headquartered in East Rutherford, NJ.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone201-804-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$534.46 million
Profitability
Miscellaneous
Employees1,228
OptionableOptionable
Cambrex (NYSE:CBM) Frequently Asked Questions
What is Cambrex's stock symbol?
Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."
How were Cambrex's earnings last quarter?
Cambrex Co. (NYSE:CBM) posted its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.59 by $0.10. The biotechnology company earned $104.62 million during the quarter, compared to analyst estimates of $122.04 million. Cambrex had a net margin of 22.67% and a return on equity of 22.20%. The company's revenue was down 7.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.55 earnings per share. View Cambrex's Earnings History.
When is Cambrex's next earnings date?
What guidance has Cambrex issued on next quarter's earnings?
Cambrex issued an update on its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of $2.95-3.09 for the period, compared to the Thomson Reuters consensus estimate of $2.79.
What price target have analysts set for CBM?
4 brokers have issued 1 year target prices for Cambrex's stock. Their predictions range from $63.00 to $75.50. On average, they anticipate Cambrex's stock price to reach $69.25 in the next twelve months. This suggests a possible upside of 59.0% from the stock's current price. View Analyst Price Targets for Cambrex.
What is the consensus analysts' recommendation for Cambrex?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.
Has Cambrex been receiving favorable news coverage?
Headlines about CBM stock have trended somewhat negative recently, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cambrex earned a news impact score of -1.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Cambrex's key competitors?
Some companies that are related to Cambrex include Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), Catalent (CTLT), United Therapeutics (UTHR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Array Biopharma (ARRY), Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY) and Agios Pharmaceuticals (AGIO).
Who are Cambrex's key executives?
Cambrex's management team includes the folowing people:
- Steven M. Klosk, President, Chief Executive Officer & Director
- Shawn P. Cavanagh, Chief Operating Officer & Executive Vice President
- Gregory P. Sargen, Chief Financial Officer
- James G. Farrell, Vice President & Controller
- Samantha M. Hanley, Secretary, Vice President & General Counsel
Who are Cambrex's major shareholders?
Cambrex's stock is owned by many different of retail and institutional investors. Top institutional investors include Copper Rock Capital Partners LLC (1.17%), Summit Creek Advisors LLC (0.68%), Peregrine Capital Management LLC (0.60%), Confluence Investment Management LLC (0.28%), Scout Investments Inc. (0.27%) and IMA Wealth Inc. (0.10%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.
Which major investors are selling Cambrex stock?
CBM stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Louisiana State Employees Retirement System, Confluence Investment Management LLC, Scout Investments Inc., IMA Wealth Inc. and 6 Meridian. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.
Which major investors are buying Cambrex stock?
CBM stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Peregrine Capital Management LLC, Bowling Portfolio Management LLC, Fox Run Management L.L.C., Campbell Newman Asset Management Inc. and State of Alaska Department of Revenue. View Insider Buying and Selling for Cambrex.
How do I buy shares of Cambrex?
Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cambrex's stock price today?
One share of CBM stock can currently be purchased for approximately $43.54.
How big of a company is Cambrex?
Cambrex has a market capitalization of $1.46 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.
What is Cambrex's official website?
How can I contact Cambrex?
Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]
MarketBeat Community Rating for Cambrex (NYSE CBM)
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
